Meeting
2023 ASCO Annual Meeting
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
Authors
Maria Pia Morelli
The University of Texas MD Anderson Cancer Center, Houston, TX
Maria Pia Morelli , Marcelo Vailati Negrao , Matthew R. Collinson-Pautz , Kamisha Jernigan , Nathan A. Demars , Aaron Weitzman , Frances Adeyemi , Victor H Carpio , Amir A. Jazaeri , Benny Johnson , Shubham Pant , Partow Kebriaei , Abhishek K Srivastava , Drew Caldwell Deniger , John Heymach , Scott Kopetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT05194735
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2547)
DOI
10.1200/JCO.2023.41.16_suppl.2547
Abstract #
2547
Poster Bd #
389
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577).
First Author: Ben C. Creelan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T-cell receptor (TCR; FH-TCR TMSLN) in patients with metastatic pancreatic ductal adenocarcinoma (mPDA).
First Author: E. Gabriela Chiorean
Poster
2022 ASCO Annual Meeting
First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.
First Author: Marcelo Vailati Negrao
Poster
2021 ASCO Annual Meeting
Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).
First Author: Adam Jacob Schoenfeld